-
2008
28 August 2008: Announcement no. 2, 2008: Zealand Pharma today announced that Dr. David H...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 2 compounds in phase II, 3 compounds ...
ZP120 Publications
Simonsen, U., Laursen, B.E. and Petersen, J.S.:
ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries
Br J Pharmacol, 2008, 153, 1185–1194
Sørensen, N.M., Hansen, L.E. and Knudsen, C.B.:
Validation of an anti-drug antibody ELISA for the detection of ZP120 antibodies in human serum
Poster for the American Association of Pharmaceutical Scientists Annual meeting, November 11-15, 2007, San Diego, CA, USA
AAPS Journal, 2007, vol. 9, No. S2, abstract W5007
Poster
Hadrup, N., Petersen, J.S., Windfeld, S., Risom, L., Andersen, C.B., Nielsen, S., Christensen, S. and Jonassen, T.E.N.:
Differential down-regulation of aquaporin-2 in rat kidney zones by peripheral nociceptin/orphanin FQ receptor agonism and vasopressin type-2 receptor antagonism
J Pharm Exp Ther, 2007, 323, 516-524
Calò, G.:
Therapeutic opportunities for nociceptin/orphanin FQ receptor ligands.
European Opioid Conference 2006, Salamanca, Spain, 19-21 April, 2006. Abstract S4
Petersen, J.S.:
ZP120 - introduction of a new `first-in-class' agent for the treatment of acute heart failure. European Opioid Conference 2006, Salamanca, Spain, 19-21 April, 2006. Abstract S4.2
Petersen, J.S.:
ZP120 – Introduction of a new “First-in-Class” agent for the treatment of acute heart failure.
Presentation at the 60th Anniversary meeting of the Danish Society of Pharmacology and Toxicology, 7-8 December 2005
Knudsen, C., Manniche, P., Jensen, T., Eeg, M., Moen, K., Thorkildsen, C., Petersen, J. and Ebbehøj, K.:
Dose-dependent pharmacokinetics of the novel peptide aquaretic ZP120 in both humans and rats.
The AAPS J, 2005, 7 (Issue 52, Supplement) Poster # T2311
Poster for AAPS Annual Meeting and Exposition, November 6-10, 2005 Nashville, TN, USA.
Knudsen,C.B., Thorkildsen, C., Petersen, J.S. and Ebbehøj, K.:
Dose-dependent pharmacokinetics of ZP120, a novel peptide aquaretic.
Poster PO-48 at Pharmaceutical Sciences Fair & Exhibition, June 12-17, 2005 Nice, France.
Drug metabolism reviews, 2005, 37 suppl. 1, A112.
Poster presentation
Hadrup, N., Petersen, J.S., Winfeldt, S., Risom, L., Christensen, S., and Janassen, T.E.N.:
Opioid receptor like-1 stimulation decreases the aquaporin-2 protein level and is a possible new treatment for hyponatremia.
Presentation at DACRA´s 2005 Summer Meeting at The Sandbjerg Estate, 9-11 June 2005 ; abstract No. 5.
Kapusta, D.R., Thorkildsen, C., Kenigs, V.A., Meier, E., Vinge, M.M., Quist, C., and Petersen, J.S.:
Pharmacodynamic Characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a Novel, Functionally Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity.
J. Pharmacol. Exp. Ther. 2005, 314, 652-660
Hadrup, N., Petersen, J.S., Windfeld, S., Risom, L., Christensen, S. and Jonassen, T.E.N.:
Opioid receptor like 1 induced aquaresis is associated with a decreased protein level and decreased apical localization of aquaporin-2 in the rat kidney cortex.
Poster B8 for Dansk Farmakologi 2005, 19 Januar, 2005, SDU, Odense, Denmark
Hadrup, N., Petersen, J.S., Praetorius, J., Meier, E., Græbe, M., Brønd, L., Staahltoft, D., Nielsen, S., Christensen, S., Kapusta, D.R. and Jonassen, T.E.N.:
Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation.
Am. J. Physiol Renal Physiol. 2004, 287, F160-F168
Jonassen, T., Hadrup, N., Broend, L., Christensen, S., Nielsen, S., and Petersen, J. S.:
The aquaretic effect of the nociceptin analogue ZP120C is associated with marked downregulation of aquaporin 2.
Oral presentation at American Heart Association Scientific Sessions 2002, Chicago, USA, November 17-20, 2002.
Circulation, 2002, 106, No. 19 (Suppl. II), p II-135, Abstract 680
Regoli, D., Calo’, G., Rizzi, A., Rizzi, D., Marzola, G., Larsen, B.D.:
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: In vitro and in vivo studies in mice.
XIVth World Congress of Pharmacology, San Francisco, USA, July 7-12, 2002.
The Pharmacologist, 2002, 44 (2), suppl. 1, A101-A102, abstract 65.6
Rizzi, A., Rizzi, D., Marzola, G., Regoli, D., Larsen, B.D., Petersen, J. and Calo', G.:
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
Br. J. Pharmacol. 2002. 137, 369-374.
Kapusta, D.R., Calo’, G. and Kenigs, V.A.:
Peripheral administration of partial agonists of the nociceptin opioid peptide (NOP) receptor produce water diuresis in conscious rats.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:A841, 2002. Poster no. 640.21
Kapusta, D.R., Kenigs, V.A., Vinge, M.M., Hansen, C., Meier, E., Thorkildsen, C., and Petersen, J.S:
ZP120C, is a peripherally acting nociceptin analogue with water diuretic and potassium sparing properties.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:841, 2002. Poster no. 640.23
Jonassen, T.E.N., Græbe, M., Staahltoft,. D., Christensen, S. and Petersen, J. S.:
Aquaretic effect of a novel nociceptin analogue ZP120C.
Experimental Biology 2002 Meeting, New Orleans, LA, USA, April 2002
FASEB J. 16:A51, 2002. Poster no. 105.3
Kapusta, D.R., Kenigs, V.A., Vinge, M.M., Thorkildsen, C., Petersen, J. S.:
ZP120: A new peripherally acting nociceptin analogue with water diuretic and potassium sparing properties.
Nedergaard Symposium, Odense, Denmark, January 24, 2002 (Abstract)
Poster presentation
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.